The current paradigm in the pharmaceutical industry is that products can only be created and developed by massive collaborative teams. Each company has to build their own costly R&D platforms and IT infrastructure. Other research industries realized decades ago that they had to share data and methods because of cost. The pharmaceutical industry has been slow to realize this. Expanding beyond our recent book (Collaborative Computational Technologies for Biomedical Research) in which a growing number of technologies, consortia, precompetitive initiatives and complex collaboration networks are described, we suggest a more open drug discovery is being enabled by collaborative computational technologies. Academia however, is not training the next generation of scientists to practice open science or even collaborate, this represents challenges and opportunities. We will describe our observations and make recommendations that impact everyone from technology developers to granting agencies. This may enable future discoveries to be made outside traditional institutions.